Landscapes / Oncology

Non-small cell lung cancer drug landscape

149 drugs in 487 active trials · Phase 3 and later · updated 16 Nov 2026

FollowEvery change as it happens, and a Monday email

Drugs149

DrugHow it worksCompanyStageNext dateDetails
ALK/ROS1 inhibitor
Pfizer · Public PFE
On the market 31 Dec 2026Phase 3 trial completes
TROP2-targeted antibody-drug conjugate
Daiichi Sankyo +1 · Public AZN
On the market 11 Jan 2027Phase 3 trial completes
EGFR inhibitor (third generation)
AstraZeneca · Public AZN
On the market 11 Jan 2027Phase 3 trial completes
Kinase inhibitor
On the market 30 Jul 2027Phase 4 trial completes
Kinase inhibitor
Pfizer · Public PFE
On the market 21 Mar 2028Phase 4 trial completes
Tyrosine kinase inhibitor
On the market 11 Jun 2029Phase 1/2 trial completes
RET inhibitor
Eli Lilly · Public LLY
On the market Oct 2029Phase 4 trial completes
Kinase inhibitor
On the market 28 Dec 2032Phase 4 trial completes
Afatinibnot checked
Kinase inhibitor
Approved —
Brigatinibnot checked
Kinase inhibitor
Approved —
Dacomitinibnot checked
Tyrosine kinase inhibitor
Pfizer · Public PFE
Approved —
Docetaxelnot checked
Microtubule inhibitor
Approved —
ALK inhibitor
Roche · Public ROG.SW
Phase 3 30 Nov 2026soonPhase 2 trial completes
Programmed death receptor-1 blocking antibody
Roche · Public ROG.SW
Phase 3 30 Nov 2026soonPhase 2 trial completes
Kinase inhibitor
Roche · Public ROG.SW
Phase 2/3 30 Nov 2026soonPhase 2 trial completes
KRAS G12C inhibitor
Roche · Public ROG.SW
Phase 3 30 Nov 2026soonPhase 2 trial completes
Tyrosine kinase inhibitor
Roche · Public ROG.SW
Phase 3 30 Nov 2026soonPhase 2 trial completes
EGFR-targeted antibody-drug conjugate
CSPC · Public 1093.HK
Phase 3 30 Nov 2026soonPhase 2 trial completes
PD-1/IL-2 bispecific fusion protein
Innovent +1 · Public 1801.HK
Phase 3 30 Nov 2026soonPhase 2 trial completes
BRAF inhibitor
Roche · Public ROG.SW
Phase 2/3 30 Nov 2026soonPhase 2 trial completes
EGFR inhibitor
Phase 3 Nov 2026soonPhase 2 trial completes
TROP2-targeted antibody-drug conjugate
Kelun-Biotech +1 · Public 6990.HK · MRK
Phase 3 Nov 2026soonPhase 3 trial completes
—
Phase 3 Nov 2026soonPhase 2 trial completes
HER2 inhibitor
Phase 3 10 Dec 2026soonPhase 3 trial completes
Pembrolizumab biosimilar candidate
Amgen · Public AMGN
Phase 3 14 Dec 2026soonPhase 3 trial completes
PD-1 antibody
Merck & Co. · Public MRK
Phase 3 15 Dec 2026soonPhase 1/2 trial completes
Tyrosine kinase inhibitor
CSPC · Public 1093.HK
Phase 3 25 Dec 2026Phase 2 trial completes
Docetaxel, albumin-bound (chemotherapy)
CSPC +1 · Public 1093.HK
Phase 2/3 25 Dec 2026Phase 2 trial completes
PD-L1 antibody
Hengrui · Public 600276.SS
Phase 3 Dec 2026Phase 1/2 trial completes
Kinase inhibitor
Pfizer · Public PFE
Phase 3 31 Dec 2026Phase 3 trial completes
Vascular endothelial growth factor inhibitor
Phase 3 Dec 2026Phase 3 trial completes
HER2-targeted antibody-drug conjugate
Phase 3 Dec 2026Phase 1/2 trial completes
TLR7/8 agonist
Phase 2/3 Dec 2026Phase 2 trial completes
Monoclonal antibody
Phase 3 Dec 2026Phase 1/2 trial completes
EGFR inhibitor (third generation)
Allist Pharmaceuticals +1
Phase 3 Dec 2026Phase 3 trial completes
CTLA-4 antibody
OncoC4 +1 · Public BNTX
Phase 3 31 Dec 2026Phase 1/2 trial completes
EGFR/HER3 bispecific antibody-drug conjugate
Sichuan Baili (Biokin, SystImmune) +1 · Public BMY
Phase 3 Dec 2026Phase 2 trial completes
Pembrolizumab biosimilar candidate
Phase 3 Dec 2026Phase 3 trial completes
HER3-targeted antibody-drug conjugate
Hengrui · Public 600276.SS
Phase 3 Dec 2026Phase 3 trial completes
—
Phase 3 Dec 2026Phase 1/2 trial completes
Tyrosine kinase inhibitor
Phase 3 31 Dec 2026Phase 1/2 trial completes
PD-L1 antibody
AstraZeneca · Public AZN
Phase 3 8 Jan 2027Phase 3 trial completes
Monoclonal antibody
AstraZeneca · Public AZN
Phase 3 8 Jan 2027Phase 3 trial completes
Monoclonal antibody
AstraZeneca · Public AZN
Phase 3 8 Jan 2027Phase 3 trial completes
TROP2-targeted antibody-drug conjugate
Gilead (Kite) · Public GILD
Phase 3 12 Jan 2027Phase 3 trial completes
MET inhibitor
HUTCHMED +1 · Public AZN
Phase 3 18 Jan 2027Phase 2 trial completes
Monoclonal antibody
Phase 3 31 Jan 2027Phase 1/2 trial completes
PD-1/VEGF bispecific antibody
Akeso +1 · Public 9926.HK · SMMT
Phase 3 Jan 2027Phase 1/2 trial completes
Programmed death receptor-1 blocking antibody
Bristol Myers Squibb · Public BMY
Phase 3 5 Feb 2027Phase 2 trial completes
ROS1/TRK/ALK inhibitor
Bristol Myers Squibb · Public BMY
Phase 3 16 Feb 2027Phase 3 trial completes
—
Phase 3 Feb 2027Phase 3 trial completes
EGFR antibody
Phase 3 26 Mar 2027Phase 3 trial completes
—
Phase 3 Mar 2027Phase 1/2 trial completes
—
Phase 3 Mar 2027Phase 1/2 trial completes
PD-1 antibody
Phase 3 31 Mar 2027Phase 1/2 trial completes
—
Henlius · Public 2696.HK
Phase 3 9 Apr 2027Phase 3 trial completes
KRAS G12D inhibitor
GenFleet Therapeutics +1
Phase 3 30 Apr 2027Phase 2 trial completes
—
Phase 2/3 30 Apr 2027Phase 1 trial completes
PD-1 antibody
Regeneron · Public REGN
Phase 2/3 Apr 2027Phase 1/2 trial completes
—
Eli Lilly · Public LLY
Phase 3 Apr 2027Phase 1/2 trial completes
EGFR inhibitor (exon 20 insertion mutations)
Taiho +1
Phase 3 27 May 2027Phase 3 trial completes
Monoclonal antibody
Daiichi Sankyo +1 · Public AZN
Phase 3 28 May 2027Phase 1/2 trial completes
CD44v9-targeted antibody-drug conjugate
Phase 2/3 30 May 2027Phase 1/2 trial completes
RAS inhibitor (active RAS, several mutations)
Phase 3 31 May 2027Phase 1/2 trial completes
Kinase inhibitor
Phase 3 31 May 2027Phase 2 trial completes
PD-1 antibody
Henlius · Public 2696.HK
Phase 2/3 18 Jun 2027Phase 2 trial completes
Vascular endothelial growth factor inhibitor
Roche · Public ROG.SW
Phase 2/3 30 Jun 2027Phase 2/3 trial completes
—
Phase 3 30 Jun 2027Phase 3 trial completes
KRAS G12C inhibitor
Amgen · Public AMGN
Phase 3 30 Jun 2027Phase 3 trial completes
Soluble LAG-3 protein (immune activator)
Phase 3 Jun 2027Phase 3 trial completes
KRAS G12D inhibitor
Phase 3 Jun 2027Phase 1/2 trial completes
PD-L1/4-1BB bispecific antibody
Phase 3 30 Jul 2027Phase 3 trial completes
Multi-specific immunoglobulin
AstraZeneca · Public AZN
Phase 3 30 Jul 2027Phase 2 trial completes
Telomere-targeting nucleotide
Phase 3 31 Jul 2027Phase 3 trial completes
PD-1/VEGF bispecific antibody
Sinocelltech · Public 688520.SS
Phase 3 Jul 2027Phase 3 trial completes
—
Phase 3 31 Aug 2027Phase 3 trial completes
HER3-targeted antibody-drug conjugate
Daiichi Sankyo +1 · Public MRK
Phase 3 1 Sep 2027Phase 2 trial completes
LAG-3 antibody
Regeneron · Public REGN
Phase 2/3 28 Sep 2027Phase 2/3 trial completes
PD-1/TIGIT bispecific antibody
AstraZeneca · Public AZN
Phase 3 29 Sep 2027Phase 1/2 trial completes
PD-1 antibody
CSPC · Public 1093.HK
Phase 3 30 Sep 2027Phase 3 trial completes
HER2/EGFR inhibitor
Phase 3 28 Oct 2027Phase 3 trial completes
MET inhibitor unconfirmed
Phase 3 31 Oct 2027Phase 3 trial completes
ROS1 inhibitor
Phase 3 31 Oct 2027Phase 3 trial completes
EGFR inhibitor (third generation)
Phase 3 31 Oct 2027Phase 3 trial completes
PD-1 antibody
AbbVie · Public ABBV
Phase 2/3 Nov 2027Phase 1/2 trial completes
Monoclonal antibody
AbbVie · Public ABBV
Phase 3 Nov 2027Phase 1/2 trial completes
EGFR inhibitor
Phase 3 1 Dec 2027Phase 2 trial completes
TIGIT antibody
Arcus Biosciences +1 · Public GILD
Phase 3 Dec 2027Phase 2 trial completes
KRAS G12C inhibitor
Phase 3 31 Dec 2027Phase 3 trial completes
ALK inhibitor
Phase 3 Dec 2027Phase 1/2 trial completes
PD-1/VEGF bispecific antibody
RemeGen +1 · Public 9995.HK · ABBV
Phase 3 31 Dec 2027Phase 3 trial completes
—
Hengrui · Public 600276.SS
Phase 3 Dec 2027Phase 1/2 trial completes
Monoclonal antibody
Gilead (Kite) · Public GILD
Phase 3 Dec 2027Phase 2 trial completes
KRAS G12C inhibitor
Merck & Co. · Public MRK
Phase 3 24 Jan 2028Phase 3 trial completes
EGFR inhibitor (third generation)
Phase 3 1 Feb 2028Phase 3 trial completes
C-Met-targeted antibody-drug conjugate
AbbVie · Public ABBV
Phase 3 Feb 2028Phase 2 trial completes
PD-L1-targeted antibody-drug conjugate
Pfizer · Public PFE
Phase 3 10 Mar 2028Phase 3 trial completes
PD-L1/VEGF-A bispecific antibody
BioNTech +1 · Public BNTX · BMY
Phase 3 15 Mar 2028Phase 2 trial completes
—
Phase 3 30 Mar 2028Phase 2 trial completes
PD-L1 antibody fused to a VEGFR1 domain (PD-L1/VEGF)
Huahai Pharmaceutical (Huaota) · Public 600521.SS
Phase 3 10 Apr 2028Phase 3 trial completes
—
Henlius · Public 2696.HK
Phase 2/3 20 Apr 2028Phase 2 trial completes
Tyrosine kinase inhibitor
Phase 3 30 Apr 2028Phase 3 trial completes
Tyrosine kinase inhibitor
Phase 3 30 Apr 2028Phase 3 trial completes
—
Phase 3 1 May 2028Phase 3 trial completes
—
Hengrui · Public 600276.SS
Phase 3 May 2028Phase 3 trial completes
Tyrosine kinase inhibitor
Phase 3 Jun 2028Phase 1/2 trial completes
PD-1/VEGF bispecific antibody
Pfizer +1 · Public PFE · 1530.HK
Phase 3 29 Jul 2028Phase 2 trial completes
Monoclonal antibody
Phase 2/3 5 Aug 2028Phase 2/3 trial completes
EGFR inhibitor (fourth generation, for the C797S mutation)
Phase 3 31 Aug 2028Phase 3 trial completes
Integrin beta-6-targeted antibody-drug conjugate
Pfizer · Public PFE
Phase 3 5 Sep 2028Phase 3 trial completes
—
Phase 3 Sep 2028Phase 3 trial completes
IL-15 receptor agonist
Phase 3 Sep 2028Phase 3 trial completes
—
Phase 3 31 Oct 2028Phase 2/3 trial completes
EGFR inhibitor (third generation)
Phase 3 31 Oct 2028Phase 1 trial completes
PD-1 antibody
Hengrui · Public 600276.SS
Phase 2/3 Oct 2028Phase 2/3 trial completes
—
Sinocelltech · Public 688520.SS
Phase 2/3 Oct 2028Phase 2 trial completes
—
Bristol Myers Squibb · Public BMY
Phase 2/3 29 Dec 2028Phase 2 trial completes
ROS1/TRK inhibitor
Nuvation Bio +1 · Public 1801.HK
Phase 3 Jan 2029Phase 3 trial completes
B7-H3-targeted antibody-drug conjugate
Phase 3 Mar 2029Phase 3 trial completes
—
Phase 3 Apr 2029Phase 3 trial completes
Tubulin-binding agent
Phase 3 1 Jun 2029Phase 3 trial completes
Personalised mRNA cancer vaccine
Merck & Co. +1 · Public MRK · MRNA
Phase 3 2 Jul 2029Phase 2 trial completes
—
AbbVie · Public ABBV
Phase 3 Dec 2029Phase 3 trial completes
EGFR antibody
Henlius · Public 2696.HK
Phase 2/3 15 Jan 2030Phase 2/3 trial completes
—
Phase 3 31 May 2030Phase 3 trial completes
KRAS G12D degrader
Phase 3 30 Jun 2030Phase 3 trial completes
Monoclonal antibody
Bristol Myers Squibb · Public BMY
Phase 3 30 Jul 2030Phase 3 trial completes
PD-L1/VEGF bispecific antibody
Henlius · Public 2696.HK
Phase 2/3 30 Dec 2030Phase 2/3 trial completes
Monoclonal antibody
Hengrui · Public 600276.SS
Phase 3 Feb 2031Phase 3 trial completes
Gene therapy: adenovirus carrying a herpes virus enzyme gene, given with a prodrug
Phase 3 22 Oct 2031Phase 3 trial completes
GARP/TGF-beta antibody
AbbVie · Public ABBV
Phase 2/3 Oct 2031Phase 2/3 trial completes
Kinase inhibitor
Eli Lilly · Public LLY
Phase 3 —
TIGIT antibody
GSK +1
Phase 3 —
PD-1/CTLA-4 bispecific antibody
Akeso · Public 9926.HK
Phase 3 —
ATR inhibitor
AstraZeneca · Public AZN
Phase 3 —
Monoclonal antibody
Phase 2/3 —
—
Phase 3 —
ALK/ROS1 inhibitor
Phase 3 —
PD-1 antibody
Phase 3 —
ALK inhibitor
Xcovery +1
Phase 3 —
—
Phase 3 —
—
Phase 3 —
MB12not checked
—
Phase 3 —
EGFR inhibitor
Phase 3 —
VEGFR2 antibody
Eli Lilly · Public LLY
Phase 3 —
—
Phase 3 —
MEK inhibitor
AstraZeneca · Public AZN
Phase 3 —
PD-1 antibody
Innovent · Public 1801.HK
Phase 3 —
CTLA-4 antibody
AstraZeneca · Public AZN
Phase 3 —

About this list

Covers
666 of 683 active trials the registry tags as Non-Small-Cell Lung Carcinoma (98%) · Breakdown
Matches
Conditions, trial titles, drug names and codes, other names, how it works and company.
Checked
144 of 149 drugs. The other 5 are marked “not checked” in the list. How we check
Sources
ClinicalTrials.gov updated 16 Nov 2026 · openFDA updated 13 Nov 2026 · Company press releases
Ask your AI about this landscape. Connect it once, then ask in plain English.
Which Phase 3 lung cancer trials read out in the next six months?
Connect your AI

Which should we check next?

Need a landscape built for you? Talk to us.

Follow Non-small cell lung cancer

Following is part of Solo: you see every change to Non-small cell lung cancer the day it happens.

Solo

$49a month

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in